Genentech enters agreement to develop autoimmune therapies

21-05-2019

Genentech enters agreement to develop autoimmune therapies

jejim / Shutterstock.com

US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.


Genentech, Parvus Therapeutics, Navacim, inflammatory bowel disease, licensing agreement, Roche

LSIPR